1764 related articles for article (PubMed ID: 19671655)
1. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
2. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
8. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
10. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
12. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
13. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
14. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
15. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
16. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
Bridgeman MB; Pathak R
Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
19. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
20. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
Austin M; Yang YC; Vittinghoff E; Adami S; Boonen S; Bauer DC; Bianchi G; Bolognese MA; Christiansen C; Eastell R; Grauer A; Hawkins F; Kendler DL; Oliveri B; McClung MR; Reid IR; Siris ES; Zanchetta J; Zerbini CA; Libanati C; Cummings SR;
J Bone Miner Res; 2012 Mar; 27(3):687-93. PubMed ID: 22095631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
